<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00167583</url>
  </required_header>
  <id_info>
    <org_study_id>AKF 105-0-0</org_study_id>
    <secondary_id>BMBF-01KG0706</secondary_id>
    <nct_id>NCT00167583</nct_id>
  </id_info>
  <brief_title>Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet`s Disease (INCYTOB)</brief_title>
  <acronym>INCYTOB</acronym>
  <official_title>Phase III Study of Recombinant Human Interferon-alpha2a Versus Cyclosporin A for the Treatment of Ocular Behcet`s Disease - a National,Randomised, Single-masked Controlled Trial (INCYTOB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if interferon-alpha2a is superior to the standard
      treatment with cyclosporin A for the treatment of severe ocular manifestations of Behcet`s
      disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Behcet`s disease is a multisystem vasculitis often involving ocular (retinal) blood vessels
      (in 70% of all cases). This form of uveitis or retinal vasculitis still leads to blindness in
      25 to 50% of the patients irrespective of immunosuppressive treatment.

      The aim of the study is to evaluate if Interferon-alpha2a is superior to the present standard
      treatment (cyclosporin A (CSA)) for severe ocular (panuveitis, posterior uveitis, retinal
      vasculitis) Behçet`s Disease (BD) and significantly improves visual prognosis and quality of
      health and life of the patients with ocular BD and is acting more rapidly than standard
      treatment. Furthermore, we want to evaluate if IFN-α induces long term remissions of ocular
      BD which can be maintained without further medical treatment.

      The patients are randomised into two treatment groups (IFN/CSA) and treated for one year
      according to an algorithm which adapts dosages to clinical course. A crossover from one
      treatment arm to the other is planned in case of inefficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of disease activity and preservation of visual acuity (monthly, at one and 2 years)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to improvement and remission</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Laboratory values for inflammatory activity (monthly)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of switches from one treatment to the other</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life for patients with low vision (monthly)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ocular and non-ocular relapses (1 year, 2 years)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the treatment-free period (second year)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Behcet's Disease</condition>
  <condition>Panuveitis</condition>
  <condition>Posterior Uveitis</condition>
  <condition>Retinal Vasculitis</condition>
  <arm_group>
    <arm_group_label>A Cyclosporin A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cyclosporin A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B Interferon alpha</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Interferon-alpha2a</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporin A</intervention_name>
    <description>3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels</description>
    <arm_group_label>A Cyclosporin A</arm_group_label>
    <other_name>Sandimmun neoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-alpha2a</intervention_name>
    <description>3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.</description>
    <arm_group_label>B Interferon alpha</arm_group_label>
    <other_name>Roferon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Behçet`s disease fulfilling the International Study Group Criteria with active pan- or
             posterior uveitis (according to the posterior uveitis scoring system) or retinal
             vasculitis and active disease according to the Behcet`s Disease activity scoring
             system.

        Exclusion Criteria:

          -  Previous treatment with interferon-α or cyclosporin A

          -  Pregnancy, breast feeding women, malignancy

          -  Renal impairment (creatinine &gt; 1.5 mg/dl)

          -  Uncontrolled hypertension or diabetes

          -  Depression or other psychic disorders(also history of depression)

          -  History of acute or chronic inflammatory joint or autoimmune disease

          -  Organ or bone marrow transplant recipient, cardiac failure &gt; NYHAIII

          -  Acute liver disease with SGPT 2x above normal

          -  White blood cell count &lt; 3500/mm3

          -  Platelet count &lt; 100000/mm3

          -  Hgb &lt; 8.5g/dl

          -  Body weight &lt;45 kg

          -  Alcohol abuse or drug abuse

          -  Mental impairment

          -  Uncooperative attitude
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ina Koetter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tuebingen University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Internal Medicine II and Department of Ophthalmology</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.medizin.uni-tuebingen.de/webim2/ifa1.htm</url>
    <description>Homepage with informations on Behcet`s Disease and on the study protocol , treatment algorithms and centres (in German)</description>
  </link>
  <reference>
    <citation>Kötter I, Günaydin I, Zierhut M, Stübiger N. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum. 2004 Apr;33(5):320-35. Review.</citation>
    <PMID>15079763</PMID>
  </reference>
  <reference>
    <citation>Kötter I, Vonthein R, Zierhut M, Eckstein AK, Ness T, Günaydin I, Grimbacher B, Blaschke S, Peter HH, Stübiger N. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial. Semin Arthritis Rheum. 2004 Apr;33(5):311-9.</citation>
    <PMID>15079762</PMID>
  </reference>
  <reference>
    <citation>Kötter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Günaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, Stübiger N. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003 Apr;87(4):423-31.</citation>
    <PMID>12642304</PMID>
  </reference>
  <reference>
    <citation>Stuebiger N, Koetter I, Zierhut M. Complete regression of retinal neovascularization after therapy with interferon alfa in Behçet's disease. Br J Ophthalmol. 2000 Dec;84(12):1437-8.</citation>
    <PMID>11186866</PMID>
  </reference>
  <reference>
    <citation>Kötter I, Aepinus C, Graepler F, Gärtner V, Eckstein AK, Stübiger N, Kaskas B, Zierhut M, Bültmann B, Kandolf R, Kanz L. HHV8 associated Kaposi's sarcoma during triple immunosuppressive treatment with cyclosporin A, azathioprine, and prednisolone for ocular Behçet's disease and complete remission of both disorders with interferon alpha. Ann Rheum Dis. 2001 Jan;60(1):83-6.</citation>
    <PMID>11114291</PMID>
  </reference>
  <reference>
    <citation>Deuter CM, Kötter I, Günaydin I, Zierhut M, Stübiger N. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a]. Ophthalmologe. 2004 Feb;101(2):129-34. German.</citation>
    <PMID>14991308</PMID>
  </reference>
  <reference>
    <citation>Kotter I, Deuter C, Stubiger N, Zierhut M. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN. J Rheumatol. 2005 Aug;32(8):1633; author reply 1634.</citation>
    <PMID>16078350</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ocular Behcet`s disease</keyword>
  <keyword>Panuveitis</keyword>
  <keyword>Posterior Uveitis</keyword>
  <keyword>Retinal vasculitis</keyword>
  <keyword>Treatment</keyword>
  <keyword>Interferon-alpha</keyword>
  <keyword>Cyclosporin A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Behcet Syndrome</mesh_term>
    <mesh_term>Panuveitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
    <mesh_term>Retinal Vasculitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

